TwitterYouTubeLinkedInEmail

mckinleymedia

Avatar

About mckinleymedia

This author has not yet filled in any details.
So far mckinleymedia has created 216 blog entries.
25 Nov, 2019

2019 AACR-NCI-EORTC (ANE) Molecular Targets: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample

22019 AACR-NCI-EORTC (ANE) Molecular Targets: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor [...]

Read More
25 Nov, 2019

2019 SITC: Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms

2019 SITC: Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Comprehensive detection of potential neoantigens and accurate prediction of their MHC presentation are critical prerequisites for selecting neoepitopes that can be used for creating personalized cancer vaccines. However, prediction models developed using in-vitro MHC-peptide purification followed by [...]

Read More
25 Nov, 2019

2019 SITC: T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome

2019 SITC: T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome The promise of immunotherapy has revealed the need for comprehensive profiling of the tumor and its immune microenvironment. This includes analysis of the T-cell receptor (TCR) repertoire, which has traditionally not been feasible with an exome/transcriptome platform. To address this challenge, [...]

Read More
14 Nov, 2019

Composite

The use of single-analyte biomarkers (e.g. PD-L1 expression) has yielded modest results in the quest to accurately predict which patients are likely to respond (or not) to immunotherapies and their combinations with other treatment modalities. In the immunotherapy age, it’s clear that more effective patient stratification techniques will require the integration of multiple biomarkers that [...]

Read More
6 Nov, 2019

Rena McClory, PhD

Rena McClory joined Personalis in 2014, and serves as Vice President, Marketing, where she established and leads marketing and product management teams in building brands and accelerating product adoption in key immune-oncology, basic research and clinical markets. She was promoted from Senior Director, Cancer Research and Clinical Services in 2015. Rena brings over 20 years [...]

Read More
31 Oct, 2019

AE Risk

For certain types of immunotherapies, the incidence of adverse events (AEs) such as cytokine release syndrome (CRS) and other immune-related AEs (irAEs) has served to temper excitement related to otherwise promising clinical outcomes. This has prompted the exploration of biomarkers that can be used to predict AE risk both before and during treatment. Cytokine [...]

Read More
31 Oct, 2019

Response

While understanding the reasons why certain patients are resistant to oncology therapies is important, it is even more critical to ensure that they are administered only to patients who are expected to respond. Therefore, the identification and use molecular markers that are predictive of response is imperative in bringing the curative potential of immuno-oncology [...]

Read More
31 Oct, 2019

Resistance

Despite the success of ICIs, the majority of initial non-responders tend to progress at a natural rate, and a significant proportion of initial responders eventually relapse. Thus, understanding the underlying biological mechanisms of primary and acquired resistance to immunotherapy has become a major focus of the field. ImmunoID NeXT provides insight into the following [...]

Read More
20 Jun, 2019

Paul Ricci

Mr. Ricci has served on our board of directors since February 2019. Since October 2018, Mr. Ricci has served as an Advisor to Lightspeed Venture Partners, an early-stage technology venture capital firm. Since September 2018, Mr. Ricci has served as an Advisor to Warburg Pincus, a private equity firm. Mr. Ricci served as Chief Executive Officer of Nuance Communications, [...]

Read More